Biomarker and Alzheimer’s disease: role of high sensitivity assays and the applications

Alzheimer's disease is a devastating neurodegenerative disease, which is the only one among the top 10 deadly diseases that have almost no treatment. FDA-approved ADUHELM® from Biogen in 2021 was the first approved Alzheimer's treatment in the past 2 decades.

Current treatment plans focus on two strategies, preventing the formation and aggregation of plague proteins called amyloids and taus, or removing such proteins. ADUHELM® adopted the later pathway. Meanwhile, from the diagnostic point-of-view, we are slightly ahead of time compared with the treatment, thanks to various new technologies. In particular, highly sensitive technology and platforms enable early diagnostics.

It has been said that the diagnosis of Alzheimer's disease enters the era of biomarkers. These two biomarkers, amyloids, and taus, defines Alzheimer's disease. In this presentation, Dr. Kai Wang, Senior Director of Biomarker Services at Frontage Laboratories, Inc, focuses on highly sensitive protein biomarker assays developed and validated at a testing laboratory and their application for the diagnosis of Alzheimer's disease.

Video thumbnail

Thank you for registering!

You may now view the resource below.